bioAffinity Technologies CFO leaves for new opportunity; J. Michael Edwards returns as interim CFO Page 1

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for non-invasive tests for the detection of early-stage cancer, today announced that Michael Dougherty has stepped down as Chief Financial Officer to accept a CFO position in the Pacific Northwest in the energy sector.

J. Michael Edwards, who served as bioAffinity’s consulting CFO from 2014 to 2023 and oversaw the company’s 2022 initial public offering, will serve as interim CFO until a permanent CFO is appointed. Dougherty will continue in the role of CFO until September 15, 2024, and will assist with the transition.